Stock Price
1.18
Daily Change
-5.60%
Yearly
-52.03%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Avita Therapeutics Inc 2.76 -0.12 -4.17% -60.17%
Cochlear 193.32 -2.21 -1.13% -2.31%
CSL 264.52 -6.73 -2.48% -3.67%
Clinuvel Pharmaceuticals Ltd 23.61 -1.74 -6.86% 8.70%
Opthea Ltd 1.27 -0.03 -2.31% -36.18%
Paradigm Biopharmaceuticals Ltd 1.58 -0.08 -4.82% -33.61%
Pacific Edge 1.27 0.02 1.60% 19.81%
PYC Therapeutics Ltd 0.13 0 0% -16.13%
Ramsay Health Care 64.53 -1.17 -1.78% 2.92%
Sonic Healthcare 38.85 -1.26 -3.14% 10.68%
Starpharma Holdings Ltd 1.10 -0.05 -3.93% -24.14%
Telix Pharmaceuticals Ltd 8.09 -0.51 -5.93% 80.98%

Indexes Price Day Year
AUALL 7490 -178.80 -2.33% 5.81%
AU200 7176 -166.60 -2.27% 5.52%

Mesoblast Ltd
Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.